$First clinical experience with fractionated intracavitary radioimmunotherapy using [177Lu]Lu-6A10-Fab fragments in patients with glioblastoma: a pilot study$

First clinical experience with fractionated intracavitary radioimmunotherapy using [177Lu]Lu-6A10-Fab fragments in patients with glioblastoma: a pilot study

Abstract Background Following resection and standard adjuvant radio- and chemotherapy, approved maintenance therapies for glioblastoma are lacking. Intracavitary radioimmunotherapy (iRIT) with 177Lu-labeled 6A10-Fab fragments targeting tumor-associated carbonic anhydrase XII and injected into the re...

Full description

Bibliographic Details
Main Authors:	Wolfgang Roll, Michael Müther, Guido Böning, Astrid Delker, Nils Warneke, Franz-Josef Gildehaus, Michael Schäfers, Walter Stummer, Reinhard Zeidler, Hans-Jürgen Reulen, Lars Stegger
Format:	Article
Language:	English
Published:	SpringerOpen 2023-09-01
Series:	EJNMMI Research
Subjects:	Radioimmunotherapy Carbonic anhydrase XII Immunoglobulin Fab fragments Glioblastoma Lutetium-177
Online Access:	https://doi.org/10.1186/s13550-023-01029-7

Similar Items

In vitro characterisation of [177Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer
by: Ashleigh Hull, et al.
Published: (2023-08-01)

Development of 177Lu-phytate Complex for Radiosynovectomy
by: Hassan Yousefnia, et al.
Published: (2013-05-01)

Single-dose anti-CD138 radioimmunotherapy: bismuth-213 is more efficient than lutetium-177 for treatment of multiple myeloma in a preclinical model
by: Nolwenn eFichou, et al.
Published: (2015-11-01)

Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach
by: Astrid Gosewisch, et al.
Published: (2018-08-01)

Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu
by: Rupali Bhardwaj, et al.
Published: (2019-07-01)

Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium
by: Kevin J. H. Allen, et al.
Published: (2019-07-01)

Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma
by: Mackenzie E. Malo, et al.
Published: (2020-11-01)

Optimization of 177Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application
by: Aylin Cankaya, et al.
Published: (2023-05-01)

Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
by: Anna Sundlöv, et al.
Published: (2018-07-01)

Evaluation of novel highly specific antibodies to cancer testis antigen Centrin‐1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer
by: Rubin Jiao, et al.
Published: (2019-09-01)

An assessment tumor targeting ability of 177Lu labeled cyclic CCK analogue peptide by binding with cholecystokinin receptor
by: Eun-Ha Cho, et al.
Published: (2016-07-01)

Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry
by: Catherine Meyer, et al.
Published: (2023-12-01)

Radionuclide Therapy of HER2-Expressing Xenografts Using [<sup>177</sup>Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
by: Yongsheng Liu, et al.
Published: (2023-04-01)

In Vivo Measurement and Characterization of a Novel Formulation of [177Lu]-DOTA-Octreotate
by: Dale Bailey, et al.
Published: (2016-01-01)

Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study
by: Seyed Ali Mirshahvalad, et al.
Published: (2023-01-01)

Radioligand Therapy with [<sup>177</sup>Lu]Lu-DOTA-TATE or [<sup>177</sup>Lu]Lu-DOTA-TATE and [<sup>90</sup>Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade
by: Adam Daniel Durma, et al.
Published: (2023-08-01)

Features and Practical Aspects of Radiochemical Purity Determination of Receptor-Specific Lu-177 Radiopharmaceuticals as Exemplified by [<sup>177</sup>Lu]Lu–PSMA-617
by: A. A. Larenkov, et al.
Published: (2022-12-01)

Inter-comparison of quantitative imaging of lutetium-177 (177Lu) in European hospitals
by: Jill Wevrett, et al.
Published: (2018-08-01)

Evaluation of the 177mLu-concentration in in-house produced 177Lu-radiopharmaceuticals and commercially available Lutathera®
by: Matthias Balzer, et al.
Published: (2023-11-01)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using <sup>177</sup>Lu-iPSMA and <sup>177</sup>Lu-DOTATOC: Experience after 905 Treatment Doses
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-07-01)

Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T
by: Julia Brosch-Lenz, et al.
Published: (2021-03-01)

Spectral Comparison of Neutron-Irradiated Natural and Enriched Ytterbium Targets for Lu-177 Production
by: M. Maiyesni, et al.
Published: (2019-11-01)

First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
by: Maryana Handula, et al.
Published: (2023-06-01)

Radiation doses from 161Tb and 177Lu in single tumour cells and micrometastases
by: Mario E. Alcocer-Ávila, et al.
Published: (2020-05-01)

<sup>177</sup>Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer
by: Evangelia-Alexandra Salvanou, et al.
Published: (2024-02-01)

Preclinical study of a new 177Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells
by: Hossein Behnammanesh, et al.
Published: (2020-07-01)

Toxicity Assessment of [<sup>177</sup>Lu]Lu−iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes
by: Tania Hernández-Jiménez, et al.
Published: (2022-11-01)

Simultaneous Visualization of <sup>161</sup>Tb- and <sup>177</sup>Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging
by: Francesca Borgna, et al.
Published: (2021-04-01)

177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry
by: Ayman Abouzayed, et al.
Published: (2023-09-01)

Combination of sunitinib and 177Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer
by: Jeannette C. Oosterwijk-Wakka, et al.
Published: (2022-10-01)

AAZTA5/AAZTA5-TOC: synthesis and radiochemical evaluation with 68Ga, 44Sc and 177Lu
by: Jean-Philippe Sinnes, et al.
Published: (2019-08-01)

Evaluation of Dosimetric Parameters for Tumor Therapy with 177Lu and 90Y Radionuclides in Gate Monte Carlo Code
by: Milad Peer-Firozjaei, et al.
Published: (2021-06-01)

Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled with <sup>68</sup>Ga and <sup>177</sup>Lu as Potential Theranostic Agents
by: Evangelia-Alexandra Salvanou, et al.
Published: (2022-07-01)

A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [<sup>177</sup>Lu]Ludotadipep for Patients with Metastatic Castration-Resistant Prostate Cancer: Phase I Clinical Trial
by: Dongho Shin, et al.
Published: (2022-12-01)

Targeted Endoradiotherapy with Lu<sub>2</sub>O<sub>3</sub>-iPSMA/-iFAP Nanoparticles Activated by Neutron Irradiation: Preclinical Evaluation and First Patient Image
by: Myrna Luna-Gutiérrez, et al.
Published: (2022-03-01)

Effect of <i>N</i>-Terminal Peptide Modifications on In Vitro and In Vivo Properties of <sup>177</sup>Lu-Labeled Peptide Analogs Targeting CCK2R
by: Anton Amadeus Hörmann, et al.
Published: (2023-02-01)

Molecular Radiotherapy with <sup>177</sup>Lu-Immunoliposomes Induces Cytotoxicity in Mesothelioma Cancer Stem Cells In Vitro
by: Tao Huang, et al.
Published: (2022-04-01)

Impact of the dead-time correction method on quantitative 177Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy
by: Alessandro Desy, et al.
Published: (2022-08-01)

Synthesis and Evaluation of <sup>177</sup>Lu-DOTA-PD-L1-i and <sup>225</sup>Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy
by: Myrna Luna-Gutiérrez, et al.
Published: (2023-08-01)

Lutetium 177-Labeled Cetuximab Evaluation for Radioimmunotherapeutic Applications
by: Kamal Yavari, et al.
Published: (2012-06-01)